US President Donald Trump has announced a 100% tariff on branded drugs imported to the US.

The shockwaves of this decision quickly reached Indian shores. Pharma majors , which have long relied on exports to the US, are now facing an uncertain earnings path. The market reaction was swift, with pharma stocks correcting sharply.

But history tells us that pharma is not a sector that stays down for long. Its defensive nature and steady demand often make it one of the first to bounce back once the dust settles.

For mutual fund investors, this turbulence could be an opportunity. But which pharma funds deserve a spot on your watchlist for 2026?

Here are 3 schemes that have outperformed the pharma index over the last 3 years…

#1 ICICI Prudential Pharma Healthcare & Diagnostics (P.H.D) Fu

See Full Page